Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children43610.24287/1726-1708-2020-19-4-198-204LITERATURE REVIEWОБЗОР ЛИТЕРАТУРЫPrognostic markers of lymphoblastic lymphomaПрогностические маркеры лимфобластной лимфомыhttps://orcid.org/0000-0002-2574-1636VolchkovE. V.ВолчковЕ. В.
Russian Federation

Egor V. Volchcov, a research technician at the Lymphoma Research Department

1 Samory Mashela St., Moscow 117997

Волчков Егор Васильевич, лаборант-исследователь отдела исследования лимфом

117997, Москва, ул. Саморы Машела, 1 

volchcov.egor@yandex.ruhttps://orcid.org/0000-0002-2352-7716OlshanskayaYu. V.ОльшанскаяЮ. В.
Russian Federation

Moscow

Москва

https://orcid.org/0000-0002-4779-1896MyakovaN. V.МяковаН. В.
Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России081220201941982042212202022122020Copyright ©; 2025, «D. Rogachev NMRCPHOI»Copyright ©; 2025, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2025«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/436

Lymphoblastic lymphoma (LBL) is the second most common non-Hodgkin's lymphoma in childhood. According to modern concepts LBL and acute lymphoblastic leukemia (ALL) are considered as manifestations of the same disease given the similar morphological substrate of the tumor – T and B lymphoblasts. The standard for the treatment of LBL is currently ALL-like riskadapted treatment protocols that allow achieving overall and event-free survival rates of 80–90%. The division into risk groups is based on the stage of the disease and the response to induction therapy. However, the problem of relapse/refractory course of the disease remains a serious problem due to the lack of sufficiently effective therapeutic options. Currently, there is a sufficient amount of clinical data that reliably shows that a number of molecular biological factors can be used to create a new system of into risk groups stratification of patients with LBL. This review focuses on the analysis of various factors that may be responsible for the prognosis of LBL in children.

Лимфобластная лимфома (ЛБЛ) – вторая по частоте встречаемости неходжкинская лимфома у детей. Согласно современным представлениям, ЛБЛ и острый лимфобластный лейкоз (ОЛЛ) рассматривают как проявления одного и того же заболевания, учитывая сходный морфологический субстрат опухоли – Т- и В-лимфобласты. Стандартом терапии ЛБЛ в настоящее время являются ОЛЛ-подобные риск-адаптированные протоколы лечения, позволяющие добиться показателей общей и бессобытийной выживаемости, достигающие 80–90%. Разделение на группы риска основано на стадии заболевания и ответе на терапию индукции. Однако проблема рецидивов/ рефрактерного течения заболевания остается серьезной ввиду отсутствия достаточно эффективных терапевтических опций. На сегодняшний день имеется достаточное количество клинических данных, достоверно показывающих, что ряд молекулярно-биологических факторов может быть использован для создания новой системы стратификации на группы риска пациентов с ЛБЛ. Настоящий обзор посвящен анализу различных факторов, которые могут быть ответственны за прогноз ЛБЛ у детей.

lymphoblastic lymphomaacute lymphoblastic leukemianon-Hodgkin lymphomaлимфобластная лимфомаострый лимфобластный лейкознеходжкинские лимфомы1. Arber D., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127 (20): 2391–405. DOI: 10.1182/blood-2016-03-643544Arber D., Orazi A., Hasserjian R., Thiele J., Borowitz M.J., Le Beau M.M., et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127 (20): 2391–405. DOI: 10.1182/blood-2016-03-6435442. Dores G., Devesa S., Curtis R., Linet M.S., Morton L.M., et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 2012; 119 (1): 34–43. DOI: 10.1182/blood-2011-04-347872Dores G., Devesa S., Curtis R., Linet M.S., Morton L.M., et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001–2007. Blood 2012; 119 (1): 34–43. DOI: 10.1182/blood-2011-04-3478723. Sant M., Allemani C., Tereanu C., De Angelis R., Capocaccia R., Visser O., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116 (19): 3724–34. DOI: 10.1182/blood-2010-05-282632Sant M., Allemani C., Tereanu C., De Angelis R., Capocaccia R., Visser O., et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116 (19): 3724–34. DOI: 10.1182/blood-2010-05-2826324. Burkhardt B., Zimmerman M., Oschlies I., Niggli F., Mann G., Parwaresch R., et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131 (1): 39–49. DOI: 10.1111/j.1365-2141.2005.05735.xBurkhardt B., Zimmerman M., Oschlies I., Niggli F., Mann G., Parwaresch R., et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005; 131 (1): 39–49. DOI: 10.1111/j.1365-2141.2005.05735.x5. Oschlies I., Burkhardt B., Salaverria I., Rosenwald A., d'Amore E.S.G., Szczepanowski M., et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011; 96 (2): 262–8. DOI: 10.3324/haematol.2010.030809Oschlies I., Burkhardt B., Salaverria I., Rosenwald A., d'Amore E.S.G., Szczepanowski M., et al. Clinical, pathological and genetic features of primary mediastinal large B-cell lymphomas and mediastinal gray zone lymphomas in children. Haematologica 2011; 96 (2): 262–8. DOI: 10.3324/haematol.2010.0308096. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon. IARC. 2008.WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. Lyon. IARC. 2008.7. Reiter A., Schrappe M., Ludwig W., Tiemann M., Parwaresch R., Zimmermann M., et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95 (2): 416–21.Reiter A., Schrappe M., Ludwig W., Tiemann M., Parwaresch R., Zimmermann M., et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95 (2): 416–21.8. Landmann E., Burkhardt B., Zimmermann M., Meyer U., Woessmann W., Klapper W., et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 2017; 102 (12): 2086–96. DOI: 10.3324/haematol.2015.139162Landmann E., Burkhardt B., Zimmermann M., Meyer U., Woessmann W., Klapper W., et al. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma. Haematologica 2017; 102 (12): 2086–96. DOI: 10.3324/haematol.2015.1391629. Sandlund J., Pui C.H., Zhou Y., Behm F.G., Onciu M., Razzouk B.I., et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia 2009; 23 (6): 1127–30. DOI: 10.1038/leu.2008.400Sandlund J., Pui C.H., Zhou Y., Behm F.G., Onciu M., Razzouk B.I., et al. Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study. Leukemia 2009; 23 (6): 1127–30. DOI: 10.1038/leu.2008.40010. Abromowitch M., Termuhlen A., Chang M., High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971. Blood 2008; 112 (11): 3610. DOI: 10.1182/blood.V112.11.3610.3610Abromowitch M., Termuhlen A., Chang M., High-Dose Methotrexate and Early Intensification of Therapy Do Not Improve 3 Year EFS in Children and Adolescents with Disseminated Lymphoblastic Lymphoma. Results of the Randomized Arms of COG A5971. Blood 2008; 112 (11): 3610. DOI: 10.1182/blood.V112.11.3610.361011. Burkhardt B., Woessmann W., Zimmermann M., Kontny U., Vormoor J., Doerffel W., et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24 (3): 491–9. DOI: 10.1200/JCO.2005.02.2707Burkhardt B., Woessmann W., Zimmermann M., Kontny U., Vormoor J., Doerffel W., et al. Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006; 24 (3): 491–9. DOI: 10.1200/JCO.2005.02.270712. Burkhardt B., Reiter A., Landmann E., Lang P., Lassay L., Dickerhoff R., et al. Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group. J Clin Oncol 2009; 27 (20): 3363–9. DOI: 10.1200/JCO.2008.19.3367Burkhardt B., Reiter A., Landmann E., Lang P., Lassay L., Dickerhoff R., et al. Poor Outcome for Children and Adolescents With Progressive Disease or Relapse of Lymphoblastic Lymphoma: A Report From the Berlin-Frankfurt-Muenster Group. J Clin Oncol 2009; 27 (20): 3363–9. DOI: 10.1200/JCO.2008.19.336713. Murphy S. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7 (3): 332–9.Murphy S. Classification, staging and end results of treatment of childhood non-Hodgkin's lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7 (3): 332–9.14. Tubergen D., Krailo M., Meadows A., Rosenstock J., Kadin M., Morse M., et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol 1995; 13 (6): 1368– 76. DOI: 10.1200/JCO.1995.13.6.1368Tubergen D., Krailo M., Meadows A., Rosenstock J., Kadin M., Morse M., et al. Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study. J Clin Oncol 1995; 13 (6): 1368– 76. DOI: 10.1200/JCO.1995.13.6.136815. Burkhardt B., Oschlies I., Klapper W., Zimmermann M., Woessmann W., Meinhardt A., et al. Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011; 25 (1): 153–60. DOI: 10.1038/leu.2010.245Burkhardt B., Oschlies I., Klapper W., Zimmermann M., Woessmann W., Meinhardt A., et al. Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 2011; 25 (1): 153–60. DOI: 10.1038/leu.2010.24516. Uyttebroeck A., Suciu S., Laureys G., Robert A., Pacquement H., Ferster A., et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 2008; 44 (6): 840–6. DOI: 10.1016/j.ejca.2008.02.011Uyttebroeck A., Suciu S., Laureys G., Robert A., Pacquement H., Ferster A., et al. Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer 2008; 44 (6): 840–6. DOI: 10.1016/j.ejca.2008.02.01117. Sandlund J., Guillerman R., Perkins S., Pinkerton C.R., Rosolen A., Patte C., et al. International Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol 2015; 33 (18): 2106–11. DOI: 10.1200/JCO.2014.59.0745Sandlund J., Guillerman R., Perkins S., Pinkerton C.R., Rosolen A., Patte C., et al. International Pediatric Non-Hodgkin Lymphoma Response Criteria. J Clin Oncol 2015; 33 (18): 2106–11. DOI: 10.1200/JCO.2014.59.074518. Coustan-Smith E., Sandlund J., Perkins S., Chen H., Chang M., Abromowitch M., et al. Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol 2009; 27: 3533–9. DOI: 10.1200/JCO.2008.21.1318Coustan-Smith E., Sandlund J., Perkins S., Chen H., Chang M., Abromowitch M., et al. Minimal Disseminated Disease in Childhood T-Cell Lymphoblastic Lymphoma: A Report From the Children's Oncology Group. J Clin Oncol 2009; 27: 3533–9. DOI: 10.1200/JCO.2008.21.131819. Stark B., Avigad S., Luria D., Manor S., Reshef-Ronen T., Avrahami G., et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer 2009; 52 (1): 20–5. DOI: 10.1002/pbc.21823Stark B., Avigad S., Luria D., Manor S., Reshef-Ronen T., Avrahami G., et al. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR). Pediatr Blood Cancer 2009; 52 (1): 20–5. DOI: 10.1002/pbc.2182320. Callens C., Baleydier F., Lengline E., Abdelali R.B., Petit A., Villarese P., et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 2012; 30 (16): 1966– 73. DOI: 10.1200/JCO.2011.39.7661Callens C., Baleydier F., Lengline E., Abdelali R.B., Petit A., Villarese P., et al. Clinical impact of NOTCH1 and/or FBXW7 mutations, FLASH deletion, and TCR status in pediatric T-cell lymphoblastic lymphoma. J Clin Oncol 2012; 30 (16): 1966– 73. DOI: 10.1200/JCO.2011.39.766121. Mussolin L., Buldini B., Lovisa F., Carraro E., Disarò S., Nigro L.L., et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience. Pediatr Blood Cancer 2015; 62 (11): 1906–13. DOI: 10.1002/pbc.25607Mussolin L., Buldini B., Lovisa F., Carraro E., Disarò S., Nigro L.L., et al. Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience. Pediatr Blood Cancer 2015; 62 (11): 1906–13. DOI: 10.1002/pbc.2560722. Thastrup M., Marquart H., Levinsen M., Grell K., Abrahamsson J., Albertsen B.K., et al. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia 2020; 34 (2): 336– 46. DOI: 10.1038/s41375-019-0570-1Thastrup M., Marquart H., Levinsen M., Grell K., Abrahamsson J., Albertsen B.K., et al. Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study. Leukemia 2020; 34 (2): 336– 46. DOI: 10.1038/s41375-019-0570-123. Popov A., Henze G., Verzhbitskaya T., Roumiantseva J., Lagoyko S., Khlebnikova O., et al. Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2019; 145 (5): 1331–9. DOI: 10.1007/s00432-019-02886-3Popov A., Henze G., Verzhbitskaya T., Roumiantseva J., Lagoyko S., Khlebnikova O., et al. Absolute count of leukemic blasts in cerebrospinal fluid as detected by flow cytometry is a relevant prognostic factor in children with acute lymphoblastic leukemia. J Cancer Res Clin Oncol 2019; 145 (5): 1331–9. DOI: 10.1007/s00432-019-02886-324. Brüggemann M., Schrauder A., Raff T., Pfeifer H., Dworzak M., Ottman O.G., et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24 (3): 521–35. DOI: 10.1038/leu.2009.268Brüggemann M., Schrauder A., Raff T., Pfeifer H., Dworzak M., Ottman O.G., et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24 (3): 521–35. DOI: 10.1038/leu.2009.26825. Brüggemann M., Kotrová M., Knecht H., Bartram J., Boudjogrha M., Bystry V., et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 2019; 33 (9): 2241–53. DOI: 10.1038/s41375-019-0496-7Brüggemann M., Kotrová M., Knecht H., Bartram J., Boudjogrha M., Bystry V., et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia 2019; 33 (9): 2241–53. DOI: 10.1038/s41375-019-0496-726. Комков А.Ю., Мирошниченкова А.М., Ольшанская Ю.В., Мякова Н.В., Дьяконова Ю.Ю., Минервина А.А. и др. Детекция перестроек иммуноглобулиновых генов при острых лимфобластных лейкозах с использованием высокопроизводительного секвенирования нового поколения. Гематология и трансфузиология 2016; 61 (4): 200-204. DOI: 10.18821/0234-5730-2016-61-4-200-204Комков А.Ю., Мирошниченкова А.М., Ольшанская Ю.В., Мякова Н.В., Дьяконова Ю.Ю., Минервина А.А. и др. Детекция перестроек иммуноглобулиновых генов при острых лимфобластных лейкозах с использованием высокопроизводительного секвенирования нового поколения. Гематология и трансфузиология 2016; 61 (4): 200-204. DOI: 10.18821/0234-5730-2016-61-4-200-20427. Komkov A., Miroshnichenkova A., Nugmanov G., Popov A., Pogorelyy M., Zapletalova E., et al. High-throughput sequencing of T-cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies. Br J Haematol 2020; 188 (5): 723–31. DOI: 10.1111/bjh.16230Komkov A., Miroshnichenkova A., Nugmanov G., Popov A., Pogorelyy M., Zapletalova E., et al. High-throughput sequencing of T-cell receptor alpha chain clonal rearrangements at the DNA level in lymphoid malignancies. Br J Haematol 2020; 188 (5): 723–31. DOI: 10.1111/bjh.1623028. Patel J., Smith L., Anderson J., Abromowitch M., Campana D., Jacobsen J., et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report. Br J Haematol 2012; 159 (4): 454– 61. DOI: 10.1111/bjh.12042Patel J., Smith L., Anderson J., Abromowitch M., Campana D., Jacobsen J., et al. The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report. Br J Haematol 2012; 159 (4): 454– 61. DOI: 10.1111/bjh.1204229. Oschlies I., Burkhardt B., ChassagneClement C., d'Amore E.S., Hansson U., Hebeda K., et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol 2011; 35 (6): 836–44. DOI: 10.1097/PAS.0b013e318213e90eOschlies I., Burkhardt B., ChassagneClement C., d'Amore E.S., Hansson U., Hebeda K., et al. Diagnosis and immunophenotype of 188 pediatric lymphoblastic lymphomas treated within a randomized prospective trial: experiences and preliminary recommendations from the European childhood lymphoma pathology panel. Am J Surg Pathol 2011; 35 (6): 836–44. DOI: 10.1097/PAS.0b013e318213e90e30. Gerr H., Zimmermann M., Schrappe M., Dworzak M., Ludwig W.-D., Bradtke J., et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol 2010; 149 (1): 84–92. DOI: 10.1111/j.1365-2141.2009.08058.xGerr H., Zimmermann M., Schrappe M., Dworzak M., Ludwig W.-D., Bradtke J., et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol 2010; 149 (1): 84–92. DOI: 10.1111/j.1365-2141.2009.08058.x31. Olshanskaya Y., Kazakova A., Tsaur G., Zerkalenkova E., Soldatkina O., Aprelova E., et al. Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB). Leuk Lymphoma 2019; 60 (2): 426–32. DOI: 10.1080/10428194.2018.1485904Olshanskaya Y., Kazakova A., Tsaur G., Zerkalenkova E., Soldatkina O., Aprelova E., et al. Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB). Leuk Lymphoma 2019; 60 (2): 426–32. DOI: 10.1080/10428194.2018.148590432. Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8 (5): 380–90. DOI: 10.1038/nri2304Aifantis I., Raetz E., Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008; 8 (5): 380–90. DOI: 10.1038/nri230433. Park M., Taki T., Oda M. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009; 145 (2): 198–206. DOI: 10.1111/j.1365-2141.2009.07607.xPark M., Taki T., Oda M. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009; 145 (2): 198–206. DOI: 10.1111/j.1365-2141.2009.07607.x34. Burkhardt B., Hermiston M. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol 2019; 185 (6): 1158–70. DOI: 10.1111/bjh.15793Burkhardt B., Hermiston M. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol 2019; 185 (6): 1158–70. DOI: 10.1111/bjh.1579335. Bonn B., Rohde M., Zimmermann M., Dworzak M., Ludwig W.-D., Bradtke J., et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 2013; 121 (16): 3153–60. DOI: 10.1182/blood-2012-12-474148Bonn B., Rohde M., Zimmermann M., Dworzak M., Ludwig W.-D., Bradtke J., et al. Incidence and prognostic relevance of genetic variations in T-cell lymphoblastic lymphoma in childhood and adolescence. Blood 2013; 121 (16): 3153–60. DOI: 10.1182/blood-2012-12-47414836. Trinquand A., Tanguy-Schmidt A., Ben Abdelali R., Lambert J., Beldjord K., Lengliné E., et al. Toward a NOTCH1/FBXW7/ RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013; 31 (34): 4333– 42. DOI: 10.1200/JCO.2012.48.5292Trinquand A., Tanguy-Schmidt A., Ben Abdelali R., Lambert J., Beldjord K., Lengliné E., et al. Toward a NOTCH1/FBXW7/ RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013; 31 (34): 4333– 42. DOI: 10.1200/JCO.2012.48.529237. Petit A., Trinquand A., Chevret S., Ballerini P., Cayuela J.-M., Grardel N., et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood 2018; 131 (3): 289–300. DOI: 10.1182/blood-2017-04-778829Petit A., Trinquand A., Chevret S., Ballerini P., Cayuela J.-M., Grardel N., et al. Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-cell acute lymphoblastic leukemia. Blood 2018; 131 (3): 289–300. DOI: 10.1182/blood-2017-04-77882938. Moorman A., Enshaei A., Schwab C., Wade R., Chilton L., Elliott A., et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014; 124 (9): 1434–44. DOI: 10.1182/blood-2014-03- 562918Moorman A., Enshaei A., Schwab C., Wade R., Chilton L., Elliott A., et al. A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia. Blood 2014; 124 (9): 1434–44. DOI: 10.1182/blood-2014-03- 56291839. Stanulla M., Dagdan E., Zaliova M., Möricke A., Palmi C., Cazzaniga G., et al. IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol 2018; 36 (12): 1240–9. DOI: 10.1200/JCO.2017.74.3617Stanulla M., Dagdan E., Zaliova M., Möricke A., Palmi C., Cazzaniga G., et al. IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia. J Clin Oncol 2018; 36 (12): 1240–9. DOI: 10.1200/JCO.2017.74.361740. Balbach S., Makarova O., Bonn B., Zimmermann M., Rohde M., Oschlies I., et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia 2016; 30 (4): 970–3. DOI: 10.1038/leu.2015.203Balbach S., Makarova O., Bonn B., Zimmermann M., Rohde M., Oschlies I., et al. Proposal of a genetic classifier for risk group stratification in pediatric T-cell lymphoblastic lymphoma reveals differences from adult T-cell lymphoblastic leukemia. Leukemia 2016; 30 (4): 970–3. DOI: 10.1038/leu.2015.20341. ClinicalTrials.gov Identifier: NCT04043494ClinicalTrials.gov Identifier: NCT0404349442. O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204 (8): 1813–24. DOI: 10.1084/jem.20070876O'Neil J., Grim J., Strack P., Rao S., Tibbitts D., Winter C., et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007; 204 (8): 1813–24. DOI: 10.1084/jem.2007087643. Oswald F., Rodriguez P., Giaimo B., Antonello Z.A., Mira L., Mittler G., et al. A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes. Nucleic Acids Res 2016; 44 (10): 4703–20. DOI: 10.1093/nar/gkw105Oswald F., Rodriguez P., Giaimo B., Antonello Z.A., Mira L., Mittler G., et al. A phospho-dependent mechanism involving NCoR and KMT2D controls a permissive chromatin state at Notch target genes. Nucleic Acids Res 2016; 44 (10): 4703–20. DOI: 10.1093/nar/gkw10544. Palomero T., Dominguez M., Ferrando A. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7 (8): 965–70. DOI: 10.4161/cc.7.8.5753Palomero T., Dominguez M., Ferrando A. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 2008; 7 (8): 965–70. DOI: 10.4161/cc.7.8.575345. Petit A., Trinquand A., Chevret S. Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines. Blood 2016; 128 (22): 1083. DOI: 10.1182/blood.V128.22.1083.1083Petit A., Trinquand A., Chevret S. Oncogenetic Risk Classification Based on NOTCH1/FBXW7/RAS/PTEN Mutation Profiles Improves Outcome Prediction in Pediatric T-Cell Acute Lymphoblastic Leukemia, Treated According the Fralle 2000 T Guidelines. Blood 2016; 128 (22): 1083. DOI: 10.1182/blood.V128.22.1083.108346. Irving J., Matheson E., Minto L., Blair H., Case M., Halsey C.,et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014; 124 (23): 3420–30. DOI: 10.1182/blood-2014-04-531871Irving J., Matheson E., Minto L., Blair H., Case M., Halsey C.,et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood 2014; 124 (23): 3420–30. DOI: 10.1182/blood-2014-04-53187147. Burkhardt B., Bruch J., M Zimmermann M., Strauch K., Parwaresch R., Ludwig W.-D., et al. Loss of heterozygosity on chromosome 6q14–q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 2006; 20 (8): 1422–9. DOI: 10.1038/sj.leu.2404275Burkhardt B., Bruch J., M Zimmermann M., Strauch K., Parwaresch R., Ludwig W.-D., et al. Loss of heterozygosity on chromosome 6q14–q24 is associated with poor outcome in children and adolescents with T-cell lymphoblastic lymphoma. Leukemia 2006; 20 (8): 1422–9. DOI: 10.1038/sj.leu.240427548. Burkhardt B., Moericke A., Klapper W., Greene F., Salzburg J., Damm-Welk C., et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 2008; 49 (3): 451–61. DOI: 10.1080/10428190701824551Burkhardt B., Moericke A., Klapper W., Greene F., Salzburg J., Damm-Welk C., et al. Pediatric precursor T lymphoblastic leukemia and lymphoblastic lymphoma: Differences in the common regions with loss of heterozygosity at chromosome 6q and their prognostic impact. Leuk Lymphoma 2008; 49 (3): 451–61. DOI: 10.1080/1042819070182455149. Yang Y., Hsiao C., Chen H., Lin K.-H., Jou S.-T., Chen J.-S., et al. Absence of biallelic TCRg deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58 (6): 846– 51. DOI: 10.1002/pbc.24021Yang Y., Hsiao C., Chen H., Lin K.-H., Jou S.-T., Chen J.-S., et al. Absence of biallelic TCRg deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia. Pediatr Blood Cancer 2012; 58 (6): 846– 51. DOI: 10.1002/pbc.2402150. Larish A., Dolan M., Casey T., Perkins J. Bilateral ovarian B-lineage lymphoblastic lymphoma with MLL gene rearrangement: a novel case in infancy. J Pediatr Hematol Oncol 2015; 37 (4): e215–7. DOI: 10.1097/MPH.0000000000000296Larish A., Dolan M., Casey T., Perkins J. Bilateral ovarian B-lineage lymphoblastic lymphoma with MLL gene rearrangement: a novel case in infancy. J Pediatr Hematol Oncol 2015; 37 (4): e215–7. DOI: 10.1097/MPH.000000000000029651. Boddu P., Yin C., Kanagal-Shamanna R., Tang G., Thakral B., Kadia T., et al. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Rep Hematol 2017; 2017: 2413587. DOI: 10.1155/2017/2413587Boddu P., Yin C., Kanagal-Shamanna R., Tang G., Thakral B., Kadia T., et al. An Unsuspected Finding of t(9;22): A Rare Case of Philadelphia Chromosome-Positive B-Lymphoblastic Lymphoma. Case Rep Hematol 2017; 2017: 2413587. DOI: 10.1155/2017/241358752. Kubota-Tanaka M., Osumi T., Miura S., Tsujimoto H., , Imamura T., Nishimura A., et al. B-lymphoblastic lymphoma with TCF3-PBX1 fusion gene. Haematologica 2019; 104 (1): e35–37. DOI: 10.3324/haematol.2018.199885Kubota-Tanaka M., Osumi T., Miura S., Tsujimoto H., , Imamura T., Nishimura A., et al. B-lymphoblastic lymphoma with TCF3-PBX1 fusion gene. Haematologica 2019; 104 (1): e35–37. DOI: 10.3324/haematol.2018.19988553. Meyer J., Zhou D., Mason C., Downie J.M., Rodic V., Abromowitch M., et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer 2017; 64 (7). DOI: 10.1002/pbc.26363Meyer J., Zhou D., Mason C., Downie J.M., Rodic V., Abromowitch M., et al. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatr Blood Cancer 2017; 64 (7). DOI: 10.1002/pbc.26363